Study of Optune in newly diagnosed GBM patients
Part of Cancer clinical trials.
This study follows patients with newly diagnosed glioblastoma who are receiving maintenance chemotherapy and starting treatment with the Optune device. It aims to see how well the device works in routine care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been newly diagnosed with glioblastoma (GBM).
- You have finished radiation and chemotherapy after surgery or a biopsy.
- You are currently in your first or second round of maintenance chemotherapy with temozolomide (TMZ).
- Your doctor has decided to start treatment with the Optune device.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the Optune device (a wearable electric field therapy) to standard chemotherapy (temozolomide) and the immunotherapy drug pembrolizumab can help people with newly diagnosed glioblastoma live longer. You may be able to join if you've completed initial radiation and chemo, and have not received certain immunotherapies before.
This trial tests whether wearing a device called Optune (which uses electric fields to slow cancer growth) before surgery helps people with glioblastoma. It is for patients who are fairly active and plan to have standard tumor removal and radiation therapy afterward.
This study tests an experimental drug, CUE-102, for people with recurrent glioblastoma. It aims to see if the drug is safe and how well it works. You may be eligible if your tumor has come back once, you have a specific genetic marker (HLA-A*0201), and you are not on other treatments.
This study tests an extra course of radiation therapy after standard treatment for glioblastoma, a type of brain cancer. The goal is to see if it helps keep the cancer from coming back.
This study tests a new medicine (MT-125) combined with standard radiation and chemotherapy for people with newly diagnosed glioblastoma that has a specific gene change (MGMT methylated). The goal is to see if it is safe and tolerable, and to look for early signs it might help.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.